Key facts
- Drug regulatory authorities are conducting inspections to ensure Good Manufacturing Practice (GMP) compliance at pharmaceutical plants.
- Multi-member teams have been constituted by several states to conduct these inspections.
- All manufacturing units, including MSMEs, are now subject to these inspections.
- A previously granted grace period for MSMEs to comply with GMP standards has ended.
Drug regulatory authorities across India have initiated a comprehensive inspection drive to verify compliance with Good Manufacturing Practices (GMP) at pharmaceutical manufacturing units. This intensified oversight aims to ensure that all facilities adhere to established standards before a GMP Certificate is issued.
Dedicated multi-member teams have been formed by several states to conduct these inspections, ensuring thoroughness and preventing any facility from bypassing the verification process. Notably, the inspections now encompass all manufacturing units without exception. This includes Micro, Small, and Medium Enterprises (MSMEs), which had previously been granted a relaxation period that concluded in January. With the grace period having expired, MSMEs can no longer defer compliance, and future inspections will be comprehensive and universally applied.